P2Y12 Receptor Antagonist

Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.

PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y₁₂ receptor antagonist with a K_i values of 24.9 nM. The P2Y₁₂ receptor plays a crucial role in platelet aggregation. Antithrombotic effect.

Selatogrel (ACT-246475) is a reversible and selective P2Y₁₂ receptor antagonist which inhibits platelet aggregation with an IC₅₀ of 8 nM. Selatogrel exhibits antithrombotic efficacy.

2-Methylthio-AMP (2-MeSAMP) is a selective and direct P2Y₁₂ antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation.

AZD1283 is a potent P2Y₁₂ receptor antagonist with a binding IC₅₀ of 11 nM and a GTPγS IC₅₀ of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders.

Elinogrel (PRT060128) is an orally active, selective, competitive, and reversible direct-acting platelet P2Y₁₂ antagonist (IC₅₀ = 20 nM). Elinogrel blocks ADP-induced signaling by directly and reversibly competing for binding to the platelet P2Y₁₂ receptor. Elinogrel exhibits rapid and potent anti-platelet aggregation and antithrombotic activities. Elinogrel is suitable for research into acute coronary syndrome and antithrombotic.

P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC₅₀ of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis.

Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

Regrelor disodium (INS 50589) is a platelet P2Y12 receptor antagonist. Regrelor disodium is a well-tolerated, reversible ADP competitive antagonist. Regrelor disodium inhibits cell proliferation. Regrelor disodium can be used in inflammation-related research.

2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct P2Y₁₂ antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation.

P2Y12 antagonist 2 is a potent P2Y₁₂ receptor antagonist. P2Y12 antagonist 2 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. P2Y12 antagonist 2 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. P2Y12 antagonist 2 can be used to research thromboembolic disorders.

Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist.

SAR216471 hydrochloride is a P2Y12 receptor antagonist. SAR216471 hydrochloride has antiplatelet and antithrombotic activities in vivo.

AR-C66096 is a potent and selective antagonist of the Gi-coupled P2Y12 receptor. AR-C66096 suppresses platelet thrombus stability under physiological flow conditions. AR-C66096 inhibits ADP-induced aggregation in whole blood aggregometry. AR-C66096 can be used for antithrombotic research.

ACT-281959 is an orally active prodrug of Selatogrel (HY-109122), a P2Y12 receptor antagonist. ACT-281959 can inhibit platelet aggregation and can be used for the research of cardiovascular disease.

(Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC₅₀ of 15 μM).

Elinogrel (Standard) (PRT060128 (Standard)) is the analytical standard of Elinogrel (HY-11021). This product is intended for research and analytical applications. Elinogrel (PRT060128) is an orally active, selective, competitive, and reversible direct-acting platelet P2Y₁₂ antagonist (IC₅₀ = 20 nM). Elinogrel blocks ADP-induced signaling by directly and reversibly competing for binding to the platelet P2Y₁₂ receptor. Elinogrel exhibits rapid and potent anti-platelet aggregation and antithrombotic activities. Elinogrel is suitable for research into acute coronary syndrome and antithrombotic.

Elinogrel (PRT060128) potassium is an orally active, selective, competitive, and reversible direct-acting platelet P2Y₁₂ antagonist (IC₅₀ = 20 nM). Elinogrel potassium blocks ADP-induced signaling by directly and reversibly competing for binding to the platelet P2Y₁₂ receptor. Elinogrel potassium exhibits rapid and potent anti-platelet aggregation and antithrombotic activities. Elinogrel potassium is suitable for research into acute coronary syndrome and antithrombotic.